Cellectis currently holds a portfolio of 18 meganucleases with modified specificity, deriving from the I-CreI meganuclease with applications in:
- Healthcare, Therapeutics - major indications are severe innate genetic diseases, DNA virus infectious diseases, transplantation and Cancer
- Agricultural biotechnology - major targets are seed improvements, biofuels and biofibers
- BioProduction - major indications are cell line and recombinant protein improvements
- BioTools - a major indication is the development of research kits for pharmacogenomic studies and in particular drug screening
A partner oriented strategy
The company has signed 48 partnerships with pharmaceutical companies (Astra-Zeneca, GSK, Shire), agricultural biotechnology groups (Limagrain, Bayer, BASF, DuPont-Pioneer HiBred) and biotech companies (Genentech, Transgenics, Lexicon). Cellectis contributes to over 20 academic partnerships including Institut Gustave Roussy cancer research centre, Paris Childrens Hospital (France), Boston Childrens Hospital or Harvard Gene Therapy Initiative (USA).
The company raised above EUR24m in an IPO on NYSE Euronext Alternext (February 2007) to increase its meganucleases production capacity to 20 products a year by the end of 2008. To date the company has raised over EUR40m both in private and public rounds.
Cellectis is listed on the NYSE Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our web site: http://www.cellectis.com.
Cellectis' Forward-Looking Statements
This communication expressly or implicitly contains certain
forward-looking statements concerning Cellectis SA and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Cellectis SA to
|SOURCE Cellectis SA|
Copyright©2008 PR Newswire.
All rights reserved